1. Antitumor activity and toxicity in animals of N-7[2-(4-nitrophenyidithio) ethyl] mitomycin C (BMY-25067)

   • William T. Bradner
   • William C. Rose
   • Alexander P. Florczyk

   Preclinical Studies Pages: S1 - S7

2. Schedule dependent potentiation of antitumor drug effects by α-difluoromethylornithine in human gastric carcinoma cells in vitro

   • Sam C. Barranco
   • Courtney M. Townsend Jr.
   • Pamella J. Ford

   Preclinical Studies Pages: S9 - S18

3. Comparative activity of four anthracyclines against heterotransplanted germ cell tumor lines

   • A. Harstrick
   • J. Casper
   • H. Poliwoda

   Preclinical Studies Pages: S19 - S24

4. Preclinical antitumor activity of a soluble etoposide analog, BMY-40481-30

   • William C. Rose
   • George A. Basler
   • Anna Maria Casazza

   Preclinical Studies Pages: S25 - S32

5. Phase I study of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, NSC 286193)

   • J. A. Maroun
   • D. J. Stewart

   Clinical Studies Pages: S33 - S39

6. Phase I trial of a 5-day course of carbetimer

   • Steven M. Grunberg
   • Elizabeth Ehler
   • Malcolm S. Mitchell

   Clinical Studies Pages: S41 - S49

7. A phase I and pharmacokinetic study of intravenous vinzolidine

   • Charles W. Taylor
   • Sydney E. Salmon
   • David S. Alberts

   Clinical Studies Pages: S51 - S57

8. Combination high-dose etoposide and vincristine infusion

   • Don V. Jackson Jr.
   • Julia M. Cruz
   • Allen R. Chauvenet

   Clinical Studies Pages: S59 - S64

9. Phase II trial of fludarabine phosphate (F-ara-AMP) in patients with advanced head and neck cancer

   • A. Mittelman
   • S. Savona
   • Z. Arlin

   Clinical Studies Pages: S65 - S67

10. Evaluation of menogaril in renal cell carcinoma

    • Ronald L. Stephens
    • Phyllis Goodman
    • Ronald B. Natale

    Clinical Studies Pages: S69 - S71

11. Phase II study of 4-demethoxydaunorubicin in previously untreated extensive disease non-small cell lung cancer

    • Theera Umsawasdi
    • Tyrone B. Felder
    • Robert A. Newman

    Clinical Studies Pages: S73 - S78

12. Phase II trial of methylglyoxal bis-guanylhydrazone (MGBG) in refractory small cell lung cancer

    • Michael S. Simon
    • John Eckenrode
    • Ronald B. Natale

    Clinical Studies Pages: S79 - S81

13. A phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma

    • Mark B. Edelstein
    • John J. Crowley
    • James S. Ungerleider

    Clinical Studies Pages: S83 - S86

14. Phase II trial of intravenous melphalan for metastatic colorectal carcinoma

    • William A. Knight III
    • Phyllis Goodman
    • Laurence H. Baker

    Clinical Studies Pages: S87 - S89

15. A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy

    • Donald L. Trump
    • John C. Marsh
    • Steven E. Vogl

    Clinical Studies Pages: S91 - S94

16. Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma

    • S. B. Kaye
    • M. Clavel
    • F. Cavalli

    Clinical Studies Pages: S95 - S99

17. Announcement

    Announcement Pages: S101 - S101